| 15.26 0.27 (1.8%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 17.97 | 1-year : | 20.99 |
| Resists | First : | 15.39 | Second : | 17.97 |
| Pivot price | 14.79 |
|||
| Supports | First : | 14.73 | Second : | 14.32 |
| MAs | MA(5) : | 15.1 |
MA(20) : | 14.8 |
| MA(100) : | 15.49 |
MA(250) : | 14.01 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 77.5 |
| RSI | RSI(14): 59.8 |
|||
| 52-week | High : | 16.86 | Low : | 11.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INVA ] has closed below upper band by 5.3%. Bollinger Bands are 14.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.31 - 15.39 | 15.39 - 15.47 |
| Low: | 14.78 - 14.89 | 14.89 - 15 |
| Close: | 15.1 - 15.26 | 15.26 - 15.41 |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Tue, 23 Apr 2024
Allspring Global Investments Holdings LLC Has $1.54 Million Stock Holdings in Innoviva, Inc. (NASDAQ:INVA) - MarketBeat
Mon, 22 Apr 2024
Hussman Strategic Advisors Inc. Sells 103,000 Shares of Innoviva, Inc. (NASDAQ:INVA) - MarketBeat
Mon, 22 Apr 2024
Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share ... - Yahoo Finance
Mon, 15 Apr 2024
INVA: 3 Biotech Stocks with Potential Gains - Watch or Buy? - StockNews.com
Mon, 04 Mar 2024
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva - PR Newswire
Thu, 29 Feb 2024
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 117.7 (%) |
| Shares Short | 11,330 (K) |
| Shares Short P.Month | 13,320 (K) |
| EPS | 2.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.65 |
| Profit Margin | 57.8 % |
| Operating Margin | 53 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | 28.9 % |
| Qtrly Rev. Growth | 30.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.91 |
| EBITDA (p.s.) | 2.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 141 (M) |
| Levered Free Cash Flow | 121 (M) |
| PE Ratio | 6.93 |
| PEG Ratio | 0.9 |
| Price to Book value | 1.43 |
| Price to Sales | 3.1 |
| Price to Cash Flow | 6.84 |
| Dividend | 0.25 |
| Forward Dividend | 0 |
| Dividend Yield | 1.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|